I must admit that the science is way over my head. But my impressions are, from what I gleaned, that the technology is very encouraging and that the people who work for the company know what they are doing. As is the case with early stage bio-companies, something could always go wrong in the clinical trials - the company can't predict with absolute certainty that their mission will be a success. However, the people at Pfizer and Gilead/Kite chose SGMO's ZFN technology over those of other companies who are trying to succeed in the gene-editing space.
From a layman's point of view, the science does make sense. Other partnerships/collaborations can possibly be agreed upon at any time. Even a buyout can't be ruled out. In conclusion, I think it's a good, speculative stock to invest in with money one can afford to lose if things should go awry, but which might reap rather sizeable gains if things go right.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.